(Total Views: 452)
Posted On: 11/02/2024 7:27:34 PM
Post# of 148863
ASC30 / Orforglipron:
Orforglipron is an oral experimental, once-daily weight loss/ type 2 diabetes medication that is easier to administer and likely to be a lot less expensive than current injectable anti-obesity/type 2 GLP-1 drugs already on the market such as Ozempic or Trulicity, which are given by injection.
Jun 28, 2023
___
Dr. Palmer came from Gannex.
100% owned by Ascletis.
Ascletis & their ASC30:
"ASC30 has two- to threefold better in vitro potency against GLP-1R when compared head-to-head with orforglipron."
"The Company expects topline data from both U.S. Phase I clinical trials in the first quarter of 2025."
https://www.prnewswire.com/news-releases/ascl...49778.html
___
Cytodyn:
"These studies will again compare leronlimab alone and in combination with other therapies, including both resmetirom, the only approved treatment for MASH, and a GLP-1 agonist in an increased number of mice...."
Don't know why Dr. J did not tell us which GLP-1, but maybe it's orforglipron ?
Maybe it's multiple GLP-1's ?
Don't have a medical clue of anything she could be considering for Leronlimab mono or a combo.
Let alone of any Ascletis / Gannex drug(s).
Passing time.
: )
____
Other Gannex info:
"we are moving forward at full speed for our global leading NASH pipeline with three different targets, FASN, THR-β and FXR.”
https://www.gannexpharma.com/portal/article/i...id/18.html
Orforglipron is an oral experimental, once-daily weight loss/ type 2 diabetes medication that is easier to administer and likely to be a lot less expensive than current injectable anti-obesity/type 2 GLP-1 drugs already on the market such as Ozempic or Trulicity, which are given by injection.
Jun 28, 2023
___
Dr. Palmer came from Gannex.
100% owned by Ascletis.
Ascletis & their ASC30:
"ASC30 has two- to threefold better in vitro potency against GLP-1R when compared head-to-head with orforglipron."
"The Company expects topline data from both U.S. Phase I clinical trials in the first quarter of 2025."
https://www.prnewswire.com/news-releases/ascl...49778.html
___
Cytodyn:
"These studies will again compare leronlimab alone and in combination with other therapies, including both resmetirom, the only approved treatment for MASH, and a GLP-1 agonist in an increased number of mice...."
Don't know why Dr. J did not tell us which GLP-1, but maybe it's orforglipron ?
Maybe it's multiple GLP-1's ?
Don't have a medical clue of anything she could be considering for Leronlimab mono or a combo.
Let alone of any Ascletis / Gannex drug(s).
Passing time.
: )
____
Other Gannex info:
"we are moving forward at full speed for our global leading NASH pipeline with three different targets, FASN, THR-β and FXR.”
https://www.gannexpharma.com/portal/article/i...id/18.html
(3)
(0)Scroll down for more posts ▼
